#Novamind inc stock trial

And our level of comfort and familiarity with these compounds really sets us in a league of our own.

And if you look at our research profile now, you know, we’re working (with) ketamine, MDMA, psilocybin, LSD-all the opportunities we have out of the lab with our licensing. The amplification of Numinus’ research capabilities was not lost of CEO Payton Nyquvest, who explained that working with a broad portfolio of compounds will help foster expansion of its clinic model:įor us, it was a big part of why this was a really really great fit for us. MAPPUSX is an extension of MAPS’ Phase 3 studies to investigate the safety and efficacy of MDMA-assisted therapy for treating severe PTSD. In combination with Numinus’ ongoing participation in an open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by Multidisciplinary Association for Psychedelic Studies (MAPS), the company will become a clinical research powerhouse.

#Novamind inc stock trial

The company will inherit a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute, as well as Novamind’s participation in Mind Medicine’s (NASDAQ:MNMD) phase IIb randomized clinical trial investigating LSD for generalized anxiety disorder. Numinus CEO, Payton Nyquvest, sat down with TDR to explain the acquisition benefits to the broader investment community.Īpart from an obvious increase in scale-including the inheritance of four clinical research sites and a bioanalytical laboratory-the acquisition will provide a myriad of advantages to propel Numinus Wellness into a leadership position in psychedelic research. The business combination will create a sizable North American platform with operations spanning 13 wellness clinics, and segues Numinus into the lucrative U.S. In a transaction that checks the boxes for research expansion, growth and scale, the company has acquired Novamind Inc. (OTC:NVMDF), a psychedelic medicine provider with a network of clinics and clinical research sites. (OTC:NUMIF) is among the first to take action. In a year where M&A activity is expected to ratchet-up in 2022, Numinus Wellness Inc.